Technology has made huge strides in not only health monitoring and disease diagnosis but also active therapeutics. It is a fast-growing health sector that has seen investments grow by 40% year on year since 2013.
A wide range of products backed by evidence and peer-reviewed studies are now available to address cognitive disorders like ADHD, autoimmune diseases, insomnia, and psychiatric disorders like schizophrenia. As a result, there is value for consumers (improved outcomes), physicians (real-time monitoring of symptoms), and investors (large market size), which can drive digital therapeutics for more cost-effective solutions in the future.
At the Biofuture conference, a panel consisting of diverse voices based on the broad spectrum of products in the digital therapeutics space discussed the evolution of digital therapeutics, how they serve unmet clinical needs, how they can redefine therapy/medicine in the future, and how to build successful and sustainable business models for the next generation of products.